drugset / Trial / NCT02989259

Apatinib for Advanced Non-squamous Head and Neck Cancer

NCT02989259 ↗

NaSingle-groupOpen-labelTreatment

Summary

In this study, the investigators try to evaluate the efficacy and safety of apatinib in advanced non-squamous head and neck cancer and to validate the correlative biomarkers.

Timeline

Start
2016-12
Primary completion
2018-12
Completion
2021-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Rivoceranib Small molecule 500 mg Oral